Genialis partnered with the Pancreatic Cancer Action Network’s Know Your Tumor program to analyze 493 pancreatic adenocarcinoma samples with krasID. The study revealed genotype specific differences in response to KRAS inhibitors, including KRAS G12D and wild type, highlighting how krasID can support more personalized treatment decisions. We continue to collaborate with PanCAN to further refine krasID and help clinicians select more effective therapies.

Genialis has teamed up with Sidra Medicine to validate biomarkers that predict how patients from the Middle East will respond to gastrointestinal cancer treatments.

In 2023, Genialis partnered with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK. CRH provided anonymized, curated datasets with ‘omics and clinical metadata to support the training and validation of Genialis RNA biomarkers.

Genialis and 4baseCare are working together to develop biomarkers that predict patient responses to standard-of-care treatments in Asia and the Middle East.

Genialis and Academia Sinica have launched an NSCLC program to identify the best treatments for early-stage and TKI-resistant patients in East Asia.